Neutropenia - Pipeline Review, H2 2015

Published: Nov, 2015 | Pages: 80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neutropenia - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Neutropenia - Pipeline Review, H2 2015', provides an overview of the Neutropenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neutropenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Neutropenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neutropenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Neutropenia Overview 9
Therapeutics Development 10
Pipeline Products for Neutropenia - Overview 10
Neutropenia - Therapeutics under Development by Companies 11
Neutropenia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Neutropenia - Products under Development by Companies 17
Neutropenia - Companies Involved in Therapeutics Development 18
Apotex, Inc. 18
Biocon Limited 19
Biogenomics Limited 20
Cellerant Therapeutics, Inc. 21
Coherus BioSciences, Inc. 22
CSL Limited 23
Dr. Reddy's Laboratories Limited 24
Inbiopro Solutions Pvt. Ltd. 25
Ligand Pharmaceuticals, Inc. 26
NAL Pharmaceuticals Ltd. 27
Prolong Pharmaceuticals 28
Richter Gedeon Nyrt. 29
Sandoz International GmbH 30
Therapeutic Proteins International, LLC 31
Toko Pharmaceutical Industries Co., Ltd. 32
USV Limited 33
Neutropenia - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
ACN-8337 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CSL-324 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
EC-18 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
filgrastim - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
filgrastim - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
filgrastim - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
filgrastim - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
granulocyte colony-stimulating factor biobetter - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IBPB-004IG - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
LG-7455 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
pegfilgrastim - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
pegfilgrastim - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
pegfilgrastim - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pegfilgrastim - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
pegfilgrastim - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
pegfilgrastim - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
pegfilgrastim - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
pegfilgrastim - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
pegfilgrastim - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
pegfilgrastim - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
pegfilgrastim - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
pegfilgrastim (recombinant) - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
romyelocel-L - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ST-7 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
tamibarotene - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Neutropenia - Recent Pipeline Updates 69
Neutropenia - Dormant Projects 73
Neutropenia - Product Development Milestones 74
Featured News & Press Releases 74
Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA 74
Oct 01, 2015: Coherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study 74
Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study 75
Dec 17, 2014: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim 76
Dec 09, 2013: Ligand Announces Positive Preclinical Data on Small-Molecule G-CSF Receptor Agonist at the 55th Annual Meeting of the American Society of Hematology 76
May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics 77
Dec 12, 2011: Ligand Announces Positive Preclinical Data On Small-Molecule GCSF Receptor Agonist At ASH Annual Meeting 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables

Number of Products under Development for Neutropenia, H2 2015 10
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Comparative Analysis by Unknown Stage Development, H2 2015 16
Products under Development by Companies, H2 2015 17
Neutropenia - Pipeline by Apotex, Inc., H2 2015 18
Neutropenia - Pipeline by Biocon Limited, H2 2015 19
Neutropenia - Pipeline by Biogenomics Limited, H2 2015 20
Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2015 21
Neutropenia - Pipeline by Coherus BioSciences, Inc., H2 2015 22
Neutropenia - Pipeline by CSL Limited, H2 2015 23
Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 24
Neutropenia - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015 25
Neutropenia - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 26
Neutropenia - Pipeline by NAL Pharmaceuticals Ltd., H2 2015 27
Neutropenia - Pipeline by Prolong Pharmaceuticals, H2 2015 28
Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2015 29
Neutropenia - Pipeline by Sandoz International GmbH, H2 2015 30
Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H2 2015 31
Neutropenia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2015 32
Neutropenia - Pipeline by USV Limited, H2 2015 33
Assessment by Monotherapy Products, H2 2015 34
Number of Products by Stage and Target, H2 2015 36
Number of Products by Stage and Mechanism of Action, H2 2015 38
Number of Products by Stage and Route of Administration, H2 2015 40
Number of Products by Stage and Molecule Type, H2 2015 42
Neutropenia Therapeutics - Recent Pipeline Updates, H2 2015 69
Neutropenia - Dormant Projects, H2 2015 73